Company Overview
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -71.06% |
| 6 Months: | -41.11% |
| 3 Months: | -22.69% |
| 1 Month: | -9.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.08 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 71.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MBIO Mustang Bio, Inc. PHARMA | 0.54 | -1.29 | $3.64M | 0.00% | -25.13% | -58.12% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 50.00K | 0 | 0 | -50.00K | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 253.00K | 885.00K | 624.00K | 670.00K | 1.06M | - |
| Operating Income | -658.00K | -843.00K | -822.00K | -1.04M | -1.67M | -7.83M | -3.31M | -5.67M | -7.08M | -15.73M | -6.48M | -5.24M | -7.66M | -11.85M | -9.75M | -10.21M | -10.00M | -15.92M | -11.52M | -14.12M | -10.43M | -15.09M | -14.44M | -17.08M | -19.64M | -18.24M | -18.85M | -16.32M | -13.89M | -10.31M | -5.23M | -8.54M | -1.46M | - | -253.00K | -885.00K | -624.00K | -670.00K | -1.06M | -1.17M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -212.00K | -885.00K | -624.00K | -670.00K | -1.06M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00K | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -153.00K | -762.00K | -468.00K | -538.00K | -955.00K | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -716.00K | -911.00K | -903.00K | -1.13M | -1.87M | -8.75M | -3.22M | -5.53M | -6.94M | -15.60M | -6.28M | -5.09M | -7.52M | -11.77M | -9.61M | -10.40M | -10.17M | -16.21M | -11.86M | -14.60M | -12.95M | -14.96M | -14.36M | -17.00M | -19.80M | -19.10M | -19.00M | -16.69M | -16.23M | -10.06M | -5.19M | -8.20M | -1.41M | - | -153.00K | -762.00K | -468.00K | -538.00K | -955.00K | -1.07M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.19 | -0.16 | -0.19 | -2.71 | -2.50 | -2.42 | -2.06 | -2.00 | -1.23 | -24.81 | -18.36 | -1.96 | - | -0.05 | -0.19 | -0.07 | - | -0.14 | -0.16 |
| R&D Expense | 500.00K | - | 500.00K | 500.00K | 500.00K | - | 500.00K | 500.00K | 500.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -11.36M | -31.79M | -31.22M | -45.88M | -56.81M | -66.72M | -76.16M | -49.26M | -16.25M | -2.43M |
| Net Income | -12.65M | -31.29M | -30.66M | -46.39M | -60.02M | -66.37M | -77.53M | -51.60M | -15.75M | -1.92M |
| Diluted EPS | - | - | - | - | - | -0.76 | -10.09 | -299.95 | -38.57 | -0.39 |
| R&D Expense | 2.00M | 100.00K | 2.10M | - | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 0 | 27.50M | 63.49M | 42.75M | 73.44M | 109.90M | - | 92.42M | 17.74M | 9.31M | 17.59M |
| Current Assets | - | - | - | - | - | - | - | 78.85M | 11.35M | 8.61M | 17.59M |
| Cash & Equivalents | - | - | - | 16.47M | 61.41M | 97.80M | - | 75.66M | 6.23M | 6.84M | 17.27M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | 299.00K | 3.88M | 402.00K | 217.00K |
| Total Liabilities | 4.13M | 3.22M | 3.66M | 6.36M | 21.79M | 11.46M | - | 46.15M | 17.62M | 13.18M | 8.06M |
| Current Liabilities | 4.13M | 3.22M | 3.61M | 5.62M | 7.77M | 9.52M | - | 15.11M | 15.37M | 12.61M | 7.91M |
| Long Term Debt | - | - | - | - | - | - | - | 27.44M | - | - | - |
| Total Debt | - | - | - | - | - | - | - | 31.38M | 2.50M | 878.00K | 0 |
| Total Equity | -4.13M | 24.28M | 59.83M | 36.40M | 51.65M | 98.44M | - | 46.27M | 123.00K | -3.87M | 9.53M |
| Shares Outstanding | - | - | - | - | - | - | - | 198.36K | 1.01M | 1.83M | 7.30M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.13M | -12.95M | -19.24M | -33.58M | -37.32M | -53.67M | -65.07M | -49.48M | -11.41M | -5.26M |
| Investing Cash Flow | 0 | -29.05M | 557.00K | 13.91M | -4.41M | -5.37M | -2.95M | 5.89M | 0 | 1.17M |
| Financing Cash Flow | 31.63M | 49.98M | 181.00K | 65.12M | 78.12M | 70.85M | 34.06M | -26.08M | 11.27M | 14.53M |
| Capital Expenditure | - | -424.00K | -6.87M | -2.35M | -1.93M | -3.99M | -2.71M | -64.00K | -0 | - |
| Free Cash Flow | - | -13.37M | -26.11M | -35.93M | -39.24M | -57.65M | -67.78M | -49.54M | -11.41M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| ROE % | -52.1% | -52.3% | -84.2% | -89.8% | -61.0% | - | -167.5% | -41,952.8% | 406.7% | -20.2% |
| ROCE % | -46.8% | -53.1% | -84.1% | -69.9% | -56.6% | - | -98.5% | -2,077.6% | 492.1% | -25.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Kestra Advisory Services, LLC | 2.93% | 196.99K | $106.32K |
| 2 | Blackrock Inc. | 1.26% | 84.75K | $45.74K |
| 3 | Citadel Advisors Llc | 0.88% | 59.46K | $32.09K |
| 4 | Geode Capital Management, LLC | 0.63% | 42.24K | $22.80K |
| 5 | CFO4Life Group, LLC | 0.50% | 33.51K | $18.09K |
| 6 | Vanguard Fiduciary Trust Co | 0.48% | 32.12K | $17.34K |
| 7 | Vanguard Capital Management LLC | 0.38% | 25.70K | $13.87K |
| 8 | Xtx Topco Ltd | 0.22% | 14.65K | $7.91K |
| 9 | Virtu Financial LLC | 0.21% | 14.36K | $7.75K |
| 10 | Two Sigma Securities, LLC | 0.20% | 13.74K | $7.42K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MBIO
Mustang Bio Stock Price Forecast. Should You Buy MBIO? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTFBvNmt1djRaSnFIS0FkN0dCUVFITzk2TXpFSVk4T1ZCeXZoMnliSWR1T2NWZ2FsMF8ycFl4UU5JQnFpNlA4bW91cA?oc=5" target="_blank">Mustang Bio Stock Price Forecast. Should You Buy MBIO?</a>  …
MBIO Should I Buy - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE1DbFU3Z0o4c1NDbjZscWljcFJ6VUFJTjVickx1NkNxZlF3OE1WbHF1ZGpnTWFudGRrMl9sNlVZZGI2SWxUS2plTVpWT21UTzZkRzd1OXRvU0ZRS0l3RUE?oc=5" target="_blank">MBIO Should I Buy</a> <font c…
Mustang Bio Inc. (MBIO) Key Financial Ratios – Valuation, Profitability & More - Value Research
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxNcVVQWDNMeWowcER6NU0zVmYzM3JVeEk4SUxvdFpuczFfZ0x0WkxrYlNFeENLM1FqaVM1YjQxMllyTEU5RXZWS200RGdORFY1V0pEdWY4SkdoZ2M5My1MY0wtRU9aOGJYR1FqcEx4Z3ZDLWl6UG5qSTA0ZjVZdU9ZdHNXYUd0eTdJc3c?oc…
Biotech Stock Mustang Bio, Inc. (Nasdaq: MBIO) Soars on Orphan Drug Designation by U.S. FDA - Investorideas.com
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPVmlYNEZGMHQzYWJHeVZrQUhUMFp5RktPNy02LVpnc0lZRlR1V3dQWDBrUGxoLWlnOE1xOGFCcVFkYS1kUGsxWE1TRm5OVjlubU9lazR2MGNOSmNLYUNsQTBrbWxkNHBUQjVzcnBlM1g1enNHdjFoNmt0VjF2Sm1EYW9HeGx0T3JmZ1ExTl…
Traders are paying attention to the gapping stocks in Friday's session. - ChartMill
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQclRPVmN2RUJpSUNFaXpwdkJtZXlBaXgwX29PV1ZYVUp6MWg4bVRwS0hOMFp1dmw2YXYyTnpDb3dwVmZvS29fVkZzUFhVaWVFSWRsaXItSnNoM1ZvYkpDazFNdlZoSHJGd01rc2tuVUE1VGpmdTlGOVlaTU1wdlNCcWF4VjAtanBKaEpzMW…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE45OHlIX1hXTmU0UXBWVktiRGlsRlJ6emVuc2RlTzA0akN3aHRTWW1yVDdoOWI3TndlMjdERW9YUS15Z1h1eGE1ZXZQWlIzTkMt?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
MBIO — Frequently Asked Questions
What is the current share price of Mustang Bio, Inc. (MBIO)?
As of 2026-09-19 21:16 PDT, Mustang Bio, Inc. (MBIO) trades at $0.54 on NasdaqCM. Its 52-week range is $0.54 to $1.87.
What is the market capitalisation of MBIO?
Mustang Bio, Inc. (MBIO) has a market capitalisation of $3.64M on NasdaqCM.
What is the P/E ratio of MBIO?
MBIO trades at a trailing price-to-earnings (P/E) ratio of -1.29. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.54.
What is the return on equity (ROE) of MBIO?
MBIO has a return on equity (ROE) of -58.12%. Its return on capital employed (ROCE) is -25.13%.
Is MBIO a good stock to buy?
This page provides a data-driven analysis of Mustang Bio, Inc. (MBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.